EYEG - アイゲ―ト・ファ―マシュ―ティカルズ (Eyegate Pharmaceuticals Inc.) アイゲ―ト・ファ―マシュ―ティカルズ

 EYEGのチャート


 EYEGの企業情報

symbol EYEG
会社名 Eyegate Pharmaceuticals Inc. (アイゲ―ト・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アイ・ゲート・ファーマシューティク(Eyegate Pharmaceuticals Inc.)は臨床段階の特殊医薬品会社。同社は、眼の疾患を治療するための薬物送達システムと治療法を開発・商業化する。臨床試験における同社の製品EGP-437は、その薬物送達システム、EyeGate II輸送システムを通じて眼組織に送達される再定式局所的に活性なコルチコステロイド、デキサメタゾン、リン酸が組み込まれている。   アイゲ―ト・ファ―マシュ―ティカルズは米国の眼科向け医薬品企業。臨床段階で、目の疾患に対する治療薬と薬物送達システムの開発、商業化に従事する。主に虹彩や毛様体に炎症を起こすブドウ膜炎や黄斑浮腫の治療薬「EGP-437」を開発、活性副腎皮質ステロイド(リン酸デキサメタゾン)を含み局所療法として使用される。本社はマサチュ―セッツ州。   EyeGate Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate's lead product, Ocular Bandage Gel ('OBG'), is based on a modified form of the natural polymer hyaluronic acid. The objective of OBG is to protect the ocular surface in order for the body to re-epithelialize the cornea and improve ocular surface integrity. The product is applied as a clear topical gel, to the damaged ocular surface, and possesses unique properties that help hydrate and protect the ocular surface to allow for wound healing. EyeGate is in clinical evaluation for two different patient populations: (1) patients undergoing photorefractive keratectomy ('PRK') surgery to demonstrate corneal wound repair after refractive surgery; and (2) patients with punctate epitheliopathies ('PE') as a result of dry eye to promote reduction of PEs.
本社所在地 271 Waverley Oaks Road Suite 108 Waltham MA 02452 USA
代表者氏名 Paul G. Chaney ポール・G・チェニー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 781-788-9043
設立年月日 38322
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数
url www.eyegatepharma.com
nasdaq_url https://www.nasdaq.com/symbol/eyeg
adr_tso
EBITDA EBITDA(百万ドル) -13.46404
終値(lastsale) 0.388
時価総額(marketcap) 16854382.44
時価総額 時価総額(百万ドル) 18.19665
売上高 売上高(百万ドル) 1.41272
企業価値(EV) 企業価値(EV)(百万ドル) 5.60164
当期純利益 当期純利益(百万ドル) -12.13099
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Eyegate Pharmaceuticals Inc revenues increased from $333K to $1.3M. Net loss decreased 17% to $5.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in SGA decrease of 55% to $184K (expense) General and Administrative Expense - Bal decrease of 6% to $2M (expense).

 EYEGのテクニカル分析


 EYEGのニュース

   Where Do Hedge Funds Stand On Eyegate Pharmaceuticals, Inc. (EYEG)?  2021/06/30 13:56:26 Insider Monkey
   Eyegate Pharmaceuticals reports Q1 results  2021/05/12 20:44:04 Seeking Alpha
   EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update  2021/05/12 20:15:00 GlobeNewswire
- PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21-
   Analysts Are Pretty Bullish EyeGate Pharmaceuticals (NASDAQ:EYEG)  2021/05/12 10:07:00 Stock Market Daily
Earnings results for EyeGate Pharmaceuticals , Analyst Opinion on EyeGate Pharmaceuticals , Earnings and Valuation of (NASDAQ:EYEG), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Analysts Are Pretty Bullish EyeGate Pharmaceuticals (NASDAQ:EYEG) appeared first on .
   Armistice Capital, Llc Purchases 1,531,101 Shares of EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) Stock  2021/01/12 09:08:44 Watchlist News
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) Director Armistice Capital, Llc bought 1,531,101 shares of the business’s stock in a transaction on Wednesday, January 6th. The stock was bought at an average price of $5.23 per share, with a total value of $8,007,658.23. The transaction was disclosed in a legal filing with the SEC, which is available at […]
   EyeGate Pharma Reports Third Quarter 2020 Financial Results and Provides Business Update  2020/11/09 21:15:00 Yahoo Finance
WALTHAM, MA / ACCESSWIRE / November 9, 2020 / EyeGate Pharmaceuticals, Inc.
   Eyegate Pharmaceuticals (NASDAQ:EYEG) Stock Passes Above 50 Day Moving Average of $3.81  2020/10/22 17:22:43 The Olympia Report
Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.81 and traded as high as $3.95. Eyegate Pharmaceuticals shares last traded at $3.82, with a volume of 17,393 shares trading hands. Several analysts have commented on the stock. Alliance Global Partners […]
   Eyegate Pharmaceuticals (NASDAQ:EYEG) Shares Cross Above 50-Day Moving Average of $3.81  2020/10/21 02:26:41 US Banking News
Eyegate Pharmaceuticals Inc (NASDAQ:EYEG)’s stock price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.81 and traded as high as $3.95. Eyegate Pharmaceuticals shares last traded at $3.82, with a volume of 17,393 shares changing hands. EYEG has been the topic of a number […]
   EyeGate Pharmaceuticals : Pharma Confirms Path Forward with FDA To Develop Combination Product | MarketScreener  2020/08/12 12:23:06 MarketScreener
EyeGate Pharmaceuticals, Inc. , a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received positive feedback following its pre-IND… | August 12, 2020
   Armistice Capital, Llc Purchases 1,531,101 Shares of EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) Stock  2021/01/12 09:08:44 Watchlist News
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) Director Armistice Capital, Llc bought 1,531,101 shares of the business’s stock in a transaction on Wednesday, January 6th. The stock was bought at an average price of $5.23 per share, with a total value of $8,007,658.23. The transaction was disclosed in a legal filing with the SEC, which is available at […]
   EyeGate Pharma Reports Third Quarter 2020 Financial Results and Provides Business Update  2020/11/09 21:15:00 Yahoo Finance
WALTHAM, MA / ACCESSWIRE / November 9, 2020 / EyeGate Pharmaceuticals, Inc.
   Eyegate Pharmaceuticals (NASDAQ:EYEG) Stock Passes Above 50 Day Moving Average of $3.81  2020/10/22 17:22:43 The Olympia Report
Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.81 and traded as high as $3.95. Eyegate Pharmaceuticals shares last traded at $3.82, with a volume of 17,393 shares trading hands. Several analysts have commented on the stock. Alliance Global Partners […]
   Eyegate Pharmaceuticals (NASDAQ:EYEG) Shares Cross Above 50-Day Moving Average of $3.81  2020/10/21 02:26:41 US Banking News
Eyegate Pharmaceuticals Inc (NASDAQ:EYEG)’s stock price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.81 and traded as high as $3.95. Eyegate Pharmaceuticals shares last traded at $3.82, with a volume of 17,393 shares changing hands. EYEG has been the topic of a number […]
   EyeGate Pharmaceuticals : Pharma Confirms Path Forward with FDA To Develop Combination Product | MarketScreener  2020/08/12 12:23:06 MarketScreener
EyeGate Pharmaceuticals, Inc. , a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received positive feedback following its pre-IND… | August 12, 2020

 関連キーワード  (医薬品 米国株 アイゲ―ト・ファ―マシュ―ティカルズ EYEG Eyegate Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)